Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96


A breast one-patient panel of heterogeneous genomes reveals genetic alterations driving DCIS into invasive lesions.

Yang M, Xu Z, Zhang QZ, Wang K, Ji XY, Xu J, Zhang JY, Niu G.

Future Oncol. 2019 Mar 19. doi: 10.2217/fon-2018-0555. [Epub ahead of print]


Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.

Castro NP, Osório CA, Torres C, Bastos EP, Mourão-Neto M, Soares FA, Brentani HP, Carraro DM.

Breast Cancer Res. 2008;10(5):R87. doi: 10.1186/bcr2157. Epub 2008 Oct 17.


Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.

Kim SY, Jung SH, Kim MS, Baek IP, Lee SH, Kim TM, Chung YJ, Lee SH.

Oncotarget. 2015 Apr 10;6(10):7597-607.


DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer.

Johnson KC, Koestler DC, Fleischer T, Chen P, Jenson EG, Marotti JD, Onega T, Kristensen VN, Christensen BC.

Clin Epigenetics. 2015 Jul 25;7:75. doi: 10.1186/s13148-015-0094-0. eCollection 2015.


Comparative analysis of loss of heterozygosity and expression profile in normal tissue, DCIS and invasive breast cancer.

Zikan M, Bohm J, Pavlista D, Cibula D.

Clin Transl Oncol. 2011 Sep;13(9):652-5. doi: 10.1007/s12094-011-0710-1.


p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias.

Done SJ, Arneson NC, Ozçelik H, Redston M, Andrulis IL.

Cancer Res. 1998 Feb 15;58(4):785-9.


Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis.

Wu SG, Zhang WW, Sun JY, He ZY.

Cancer Manag Res. 2018 Mar 19;10:527-534. doi: 10.2147/CMAR.S154656. eCollection 2018.


Nuclear cytometric changes in breast carcinogenesis.

Mommers EC, Poulin N, Sangulin J, Meijer CJ, Baak JP, van Diest PJ.

J Pathol. 2001 Jan;193(1):33-9.


Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.

Elsarraj HS, Hong Y, Valdez KE, Michaels W, Hook M, Smith WP, Chien J, Herschkowitz JI, Troester MA, Beck M, Inciardi M, Gatewood J, May L, Cusick T, McGinness M, Ricci L, Fan F, Tawfik O, Marks JR, Knapp JR, Yeh HW, Thomas P, Carrasco DR, Fields TA, Godwin AK, Behbod F.

Breast Cancer Res. 2015 Sep 17;17:128. doi: 10.1186/s13058-015-0630-z.


Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer.

Muggerud AA, Rønneberg JA, Wärnberg F, Botling J, Busato F, Jovanovic J, Solvang H, Bukholm I, Børresen-Dale AL, Kristensen VN, Sørlie T, Tost J.

Breast Cancer Res. 2010;12(1):R3. doi: 10.1186/bcr2466. Epub 2010 Jan 7.


Blurry boundaries: do epithelial borderline lesions of the breast and ductal carcinoma in situ have similar rates of subsequent invasive cancer?

Choi DX, Eaton AA, Olcese C, Patil S, Morrow M, Van Zee KJ.

Ann Surg Oncol. 2013 Apr;20(4):1302-10. doi: 10.1245/s10434-012-2719-2. Epub 2012 Nov 19.


A Molecular Portrait of High-Grade Ductal Carcinoma In Situ.

Abba MC, Gong T, Lu Y, Lee J, Zhong Y, Lacunza E, Butti M, Takata Y, Gaddis S, Shen J, Estecio MR, Sahin AA, Aldaz CM.

Cancer Res. 2015 Sep 15;75(18):3980-90. doi: 10.1158/0008-5472.CAN-15-0506. Epub 2015 Aug 6.


Epithelial cells captured from ductal carcinoma in situ reveal a gene expression signature associated with progression to invasive breast cancer.

Elias EV, de Castro NP, Pineda PH, Abuázar CS, Bueno de Toledo Osorio CA, Pinilla MG, da Silva SD, Camargo AA, Silva WA Jr, E Ferreira EN, Brentani HP, Carraro DM.

Oncotarget. 2016 Nov 15;7(46):75672-75684. doi: 10.18632/oncotarget.12352.


Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.

Muggerud AA, Hallett M, Johnsen H, Kleivi K, Zhou W, Tahmasebpoor S, Amini RM, Botling J, Børresen-Dale AL, Sørlie T, Wärnberg F.

Mol Oncol. 2010 Aug;4(4):357-68. doi: 10.1016/j.molonc.2010.06.007. Epub 2010 Jun 26.


Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast.

Buerger H, Simon R, Schäfer KL, Diallo R, Littmann R, Poremba C, van Diest PJ, Dockhorn-Dworniczak B, Böcker W.

Mol Pathol. 2000 Jun;53(3):118-21.


Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade.

Mommers EC, Leonhart AM, Falix F, Michalides R, Meijer CJ, Baak JP, Diest PJ.

J Pathol. 2001 Jul;194(3):327-33.


Patterns of chromosomal alterations in breast ductal carcinoma in situ.

Hwang ES, DeVries S, Chew KL, Moore DH 2nd, Kerlikowske K, Thor A, Ljung BM, Waldman FM.

Clin Cancer Res. 2004 Aug 1;10(15):5160-7.


Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis.

Fleischer T, Frigessi A, Johnson KC, Edvardsen H, Touleimat N, Klajic J, Riis ML, Haakensen VD, Wärnberg F, Naume B, Helland A, Børresen-Dale AL, Tost J, Christensen BC, Kristensen VN.

Genome Biol. 2014;15(8):435. doi: 10.1186/PREACCEPT-2333349012841587. Epub 2014 Aug 22.


Genetic mutations and expression of p53 in non-invasive breast lesions.

Mao X, Fan C, Wei J, Yao F, Jin F.

Mol Med Rep. 2010 Nov-Dec;3(6):929-34. doi: 10.3892/mmr.2010.353. Epub 2010 Aug 26.


Supplemental Content

Support Center